Publication | Closed Access

First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers

Therapeutic Drug MonitoringMultiple DosesHealthy Male VolunteersPharmacologyPharmacotherapyDutpase InhibitorMedicineDrug Discovery